Employees: 1,137
Size Kwality Pharmaceuticals (KPL.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $467M, the 877th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹4,208 on 18 Nov 2026.
Performance Over six months the shares gained 110.3%, against -8.3% for the median peer and +3.8% for the India market (cap-weighted) — highest of 20 in its peer set.
Growth Revenue grew 47.7% over the last twelve months (peer median +12.5%); the operating margin is 22.3% (peer median 0.1%).
Valuation It trades at 7.2× enterprise value to sales against a peer median of 4.6× (7th most expensive of 19).
Capital Return on invested capital runs 7.5 points above its cost of capital (12.3% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹6.24B | ₹5.03B | ₹3.70B | ₹3.07B | ₹2.51B |
| Revenue growth | — | +36% | +21% | +22% | — |
| Gross profit | ₹2.22B | ₹1.44B | ₹999M | ₹750M | ₹754M |
| EBITDA | ₹1.60B | ₹1.21B | ₹834M | ₹696M | ₹630M |
| Net income | ₹960M | ₹673M | ₹398M | ₹238M | ₹194M |
| Free cash flow | n/a | -₹387M | ₹188M | ₹24.7M | -₹61.7M |
| Capital expenditure | n/a | ₹489M | ₹288M | ₹306M | ₹504M |
| Total debt | ₹1.46B | ₹1.31B | ₹1.12B | ₹981M | ₹903M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | KPL.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +25.0% | -3.2% | 2nd highest of 21 |
| 6-month return | +110.3% | -8.3% | highest of 20 |
| Distance from 52-week high | -0.6% | -38.2% | highest of 21 |
| Revenue growth (TTM) | +47.7% | +12.5% | 3rd highest of 20 |
| Operating margin | 22.3% | 0.1% | 2nd highest of 19 |
| EV / Sales | 7.2× | 4.6× | 7th most expensive of 19 |
| ROIC minus cost of capital | +7.5 pp | -5.4 pp | highest of 17 |
| EV / EBITDA | 28.2× | 17.7× | most expensive of 5 |
| Net debt / EBITDA | 0.9× | 1.8× | 2nd least indebted of 5 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Kwality Pharmaceuticals KPL.NS | India | $467M | +110% | +48% | 22% | 7.2× | n/a | n/a |
| Capricor Therapeutics CAPR | United States | $467M | -70% | -100% | n/a | n/a | n/a | n/a |
| Zhejiang Yatai Pharmaceutical 002370.SZ | China | $468M | -32% | -4% | -11% | 8.8× | n/a | n/a |
| Evolus EOLS | United States | $468M | +7% | +14% | -5% | 1.8× | n/a | n/a |
| Handa Pharmaceuticals 6620.TWO | Taiwan | $469M | +45% | -16% | 30% | 16.6× | 24.8% | +126.7% |
| Hainan Shuangcheng Pharmaceuticals 002693.SZ | China | $465M | -28% | +40% | 13% | 10.8× | 44.1% | +1.0% |
| BlossomHill Therapeutics BLSM | United States | $464M | n/a | n/a | n/a | n/a | n/a | n/a |
| ChengDa PharmaCeuticals 301201.SZ | China | $472M | -47% | +27% | -9% | 4.8× | n/a | n/a |
| YungShin Global 3705.TW | Taiwan | $472M | +5% | -5% | 15% | 2.0× | -3.8% | +0.7% |
| Aquestive Therapeutics AQST | United States | $475M | -9% | +13% | -114% | 10.9× | n/a | n/a |
| Assembly Biosciences ASMB | United States | $458M | -15% | +80% | -32% | 2.2× | n/a | n/a |
| SMS Pharmaceuticals SMSPHARMA.NS | India | $477M | +16% | +13% | 16% | 4.9× | n/a | n/a |
| Shanghai Fudan Forward S&T 600624.SS | China | $478M | 0% | -14% | -34% | 6.4× | n/a | n/a |
| Hansa Biopharma HNSA.ST | Sweden | $479M | +39% | +69% | -190% | 14.9× | -4.7% | +105.3% |
| REGENXBIO RGNX | United States | $480M | +22% | -5% | -120% | 3.1× | n/a | n/a |
| Shanghai MicuRx Pharmaceutical 688373.SS | China | $481M | -8% | +23% | -61% | 19.0× | n/a | n/a |
| Gufic Biosciences GUFICBIO.NS | India | $452M | +48% | +17% | 14% | 4.3× | n/a | n/a |
| Pulike Biological Engineering 603566.SS | China | $449M | -21% | -9% | 5% | 2.4× | 4.5% | +3.3% |
| Hefei Lifeon Pharmaceutical 003020.SZ | China | $486M | -21% | -1% | 10% | 2.0× | n/a | n/a |
| Nanjing Hicin Pharmaceutical 300584.SZ | China | $487M | -29% | +32% | 17% | 4.3× | 3.3% | -1.1% |
| Dong-A Socio 000640.KS | South Korea | $447M | -8% | +11% | 7% | 0.7× | -6.6% | +12.8% |